GI Cancer
22
5
5
8
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
9.1%
2 terminated out of 22 trials
80.0%
-6.5% vs benchmark
5%
1 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (22)
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
Avera Cancer Sequencing and Analytics Protocol (ASAP)
Improving Diagnosis and Treatment for Patients With Rectal Cancer
Gustabor Phase 1 - AI-based Creation of a Nutritional Plan to Compensate for Chemotherapy-induced Taste Disorders
Prevalence of Types and Patterns of Gastrointestinal Polyps in Assiut University Hospitals ( Cross Sectional Study
The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
Effect of Geriatric Intervention in Frail Patients with Gastric, Biliary, and Pancreatic Cancer Receiving Palliative Chemotherapy
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
Exercise Intervention Prior to CRS-HIPEC: Feasibility & Impact
Genomics and Prognosis in GI Cancers
Geriatric Communication Skills Training Program for Oncology Clinicians
Mobile APP Utilization for Enhanced Post-Operative Nutritional Recovery
Microbiome in Colorectal Cancer Onset and Progression
CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab or Encorafenib + Cetuximab in Subjects With Advanced GI Tumors (Keynote 596)
Pilot Study of a Pharmacy Intervention for Older Adults With Cancer
Macroscopic on Cite Evaluation of EUS-FNA Specimen With 22 G Needle
Comparison of a Web-based Advance Directive to a Standard Advance Directive
Development of Early Detection Signs for Gastrointestinal Cancer
Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)
Trial of Ascertaining Individual Preferences for Loved One's Role in End-of-Life